ChemoCentryx
is a California-based biopharmaceutical company that develops orally-administered therapeutics for the treatment of cancer, inflammatory and autoimmune diseases... Read moreChemoCentryx
is a California-based biopharmaceutical company that develops orally-administered therapeutics for the treatment of cancer, inflammatory and autoimmune diseases... Read more
President & CEO
Thomas J. Schall
News
Jul 20, 2026
PR Newswire
Press Release: ChemoCentryx : Notice of Proposed Settlement of Class Action Announced in ChemoCentryx Securities Litigation
Jul 03, 2026
StartupHub.ai
ChemoCentryx: ChemoCentryx Data Fraud Allegations Surface
Aug 18, 2025
Law 360
ChemoCentryx: Pharma Company Wins Investor Suit Over Drug Safety Claims
Oct 21, 2022
The Business Journals: Los Angeles Biz
ChemoCentryx: Amgen completes purchase of ChemoCentryx for $3.7 billion
Oct 20, 2022
MedicalMarketing& Media
ChemoCentryx: Amgen closes ChemoCentryx deal for $3.7B
Oct 20, 2022
BioSpace
ChemoCentryx: AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
Oct 19, 2022
Seeking Alpha
ChemoCentryx: ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 05, 2022
MarketScreener
ChemoCentryx: ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Aug 09, 2022
MarketScreener
ChemoCentryx: ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call
Aug 09, 2022
Owler
ChemoCentryx, Inc.: ChemoCentryx's revenue changed from $27.33M in Mar 2022 to $37.28M in Jun 2022
ChemoCentryx Competitors
1
2
3
4
5
6
7
8
9
10